Following FDA warnings about the cancer risk, a growing number of hospitals and medical institutions are abandoning the devices during laparoscopic hysterectomy procedures and uterine fibroid removal surgeries, due to concerns that they spread undiagnosed sarcomas throughout the pelvis and abdomen.

On Wednesday, Cleveland Clinic and the University of Pennsylvania Health System were the latest leading institutions to announce that morcellators will no longer be used for uterine fibroid treatments during a hysterectomy or myomectomy. The hospitals follow Brigham and Women’s Hospital and Massachusetts General Hospital, who made similar decisions earlier this month.